NAYA Biosciences Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel peptide- and antibody-derived therapeutics for oncology, metabolic and immune-mediated diseases. The company’s proprietary “i-body” platform combines the binding specificity of antibodies with the stability and manufacturability of small peptides, enabling the design of drug candidates that can be administered by subcutaneous injection and penetrate solid tissues effectively. NAYA focuses its pipeline on areas of high unmet medical need, including diabetic complications, nonalcoholic steatohepatitis (NASH) and tumor immunotherapy.
The company’s lead program, NBL-101, is a peptide-based candidate targeting receptors involved in diabetic foot ulcer healing, with preclinical data demonstrating enhanced angiogenesis and wound closure in animal models. Additional early-stage assets include NBL-202, designed to modulate key pathways in NASH, and NBL-303, an immuno-oncology i-body that binds novel tumor antigens to stimulate T-cell responses. NAYA advances these programs through integrated medicinal chemistry, protein engineering and translational biology conducted at its U.S. headquarters and research sites in Asia.
Since its founding in 2018, NAYA has built a multidisciplinary team and established collaborations with leading academic centers in North America and Europe. The company completed a Series A financing in 2020 and has progressed its most advanced candidates through IND-enabling studies. Its global footprint supports both preclinical research and manufacturing scale-up in preparation for future clinical trials.
Leadership at NAYA Biosciences is headed by CEO Dr. Jian Xu, whose prior roles include research leadership at major biopharma firms, alongside a management team with deep expertise in peptide biology, clinical development and regulatory affairs. With a focus on translating innovative science into first-in-class medicines, NAYA aims to address chronic and life-threatening conditions through differentiated therapeutic solutions in markets around the world.
AI Generated. May Contain Errors.
